Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fresh Tracks Therapeutics Inc V.BBI


Primary Symbol: FRTX

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.


GREY:FRTX - Post by User

Comment by Maxmoeon Nov 29, 2019 4:31pm
166 Views
Post# 30407069

RE:RE:RE:RE:RE:RBC Estimate $17.64/boe Netback in 2020.

RE:RE:RE:RE:RE:RBC Estimate $17.64/boe Netback in 2020.Oh, and as you can see, neither netback,nor cashflow, are numbers you can hang your hat on in isolation. Just parts of the puzzle. Cpg is selling for < 2x cashflow for good reasons and because it's just absurdly cheap like the whole energy sector. My point was not to get too excited with quick back of envelope valuations based on netbacks x boe/d, or whatever that number was you wanted to put an 18x multiple on. Just trying to help. Like I said, like the target, love the enthusiasm but please don't bet the farm based on your math. 

<< Previous
Bullboard Posts
Next >>